New clinical trial tests radiotracer for improved imaging of metastatic prostate cancer

Most forms of prostate cancer have receptors for prostate-specific membrane antigen (PSMA), a protein that helps fuel the development of prostate cancer cells. Investigators are studying if a radiotracer that binds to PSMA may improve imaging methods to find sites of metastatic prostate cancer. Read more...

Anatomy of female urinary system

Clinical trial tests a PARP inhibitor in urothelial cancer with DNA-repair defects

Apr 18, 2019

Urothelial carcinoma (UC), or bladder cancer, is the most common cancer of the urinary tract with limited treatment options. A new clinical trial aims to see how this type of cancer reacts to olaparib, a drug designed to target cancers that have defective DNA-repair mechanisms in their cells by inhibiting the action of PARP, an enzyme that can repair breaks in DNA. Read more...

Rania Labib

African Postdoctoral Training Initiative fellow looks forward to collaborating within NCI

Apr 18, 2019

Rania Labib, Ph.D., is a postdoctoral fellow in the NIH African Postdoctoral Training Initiative (APTI) working in the lab of Beverly Mock, Ph.D., Deputy Chief of the Laboratory of Cancer Biology and Genetics. As part of the fellowship, she will spend two years at NCI conducting initial experiments in Dr. Mock’s lab, where she hopes to make a difference in possible treatment options for children with Burkitt’s lymphoma.  Read more...

Three-dimensional structure of HIV infected and uninfected T cells interacting

Envelope glycoprotein mutations allow HIV-1 to escape antiretroviral therapy in a lab-based study

Apr 12, 2019

CCR investigators have discovered that HIV-1 can compensate for a variety of mutations that block its replication by acquiring mutations in the envelope glycoprotein. Because antiretroviral therapies work by inhibiting viral replication, these findings may have implications for HIV-1 drug resistance. Read more...

Travis, an NF1 patient

MEK inhibitor selumetinib granted breakthrough designation by FDA to treat neurofibromatosis type 1 in pediatric patients

Apr 12, 2019

The U.S. Food and Drug Administration last week granted breakthrough therapy designation for the MEK 1/2 inhibitor selumetinib. The designation is for the treatment of pediatric patients aged three years and older with neurofibromatosis type 1 (NF1) symptomatic and/or progressive, inoperable plexiform neurofibromas (PN), a rare, incurable genetic condition. Read more...

Elaine Jaffe

Elaine Jaffe receives the 2019 USCAP Board’s Distinguished Pathologist award

Apr 11, 2019

Elaine Jaffe, M.D., Senior Investigator in the Laboratory of Pathology, has received the 2019 United States and Canadian Academy of Pathology (USCAP) Board’s Distinguished Pathologist award. The award recognizes an individual for making major contributions to pathology over the years.  Read more...

Elaine Jaffe receives the 2019 USCAP Board’s Distinguished Pathologist award
Colon cancer cells

New study delivers chemotherapy to the liver for metastatic colorectal cancer patients

Apr 3, 2019

In some patients, colorectal cancer spreads only to the liver. Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center. Read more...

CCR DoD grant recipients

CCR staff receive funding from the Department of Defense

Apr 2, 2019

Congratulations to the CCR staff who have received funding from the Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP). The CDMRP office manages medical research programs in breast, prostate and ovarian cancers, neurofibromatosis, military health and other specified areas. Read more...

Stephanie Goff

Stephanie Goff featured in an episode of The Doctors

Apr 1, 2019

Stephanie Goff, M.D., Associate Research Physician in CCR’s Surgery Branch, was recently featured on The Doctors. In the clip, she discusses how harnessing the body’s own immune system and adoptive cell transfer (ACT) can treat certain types of cancer. Read more...

Stephanie Goff featured in an episode of The Doctors
Patient-derived glioma stem cells

New clinical trial will determine if gliomas respond to immunotherapy

Apr 1, 2019

Gliomas make up about 80 percent of all malignant brain tumors. A new clinical trial at the Center for Cancer Research is investigating if the immunotherapy drug nivolumab is beneficial to patients with gliomas.  Read more...

Artistic rendering of a T cell immersed in the tumor microenvironment exposed to high levels of potassium

Harnessing T-cell “stemness” could enhance cancer immunotherapy

Mar 28, 2019

A new study led by Nicholas Restifo, M.D., Senior Investigator in CCR’s Surgery Branch, sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Sciencesuggest a way to enhance the effectiveness of immunotherapies for cancer treatment.  Read more...

Harnessing T-cell “stemness” could enhance cancer immunotherapy